Yilmaz Ismail, Yilmazer Cuneyt, Erkan Alper Nabi, Aslan Sundus Gencay, Ozluoglu Levent N
Department of Otolaryngology Head and Neck Surgery, Adana Teaching and Medical Research Center, Baskent University Faculty of Medicine, Turkey.
Am J Otolaryngol. 2005 Mar-Apr;26(2):113-7. doi: 10.1016/j.amjoto.2004.11.001.
To investigate the effects of intratympanic dexamethasone injection, which is done because of tinnitus, on transient evoked otoacoustic emission (TEOAE) and so determine whether given dexamethasone cause any damage in the inner ear.
Twenty-six patients, aged between 32 and 75, with subjective tinnitus, were randomly selected. The selected patients were the ones whose improvement had not been achieved through minimum 6 months' medical therapy (eg, Ginkgo biloba extract EGb 761, betahistidine, and trimetazidin) and who were free of systemic or otolaryngologic disease (hypertension, diabetes mellitus, hypo/hypertyroidi, hypercholesterolemia, Meniere disease, and otosclerosis). Before and after the injections, audiometry including high-frequency tinnitus matching and TEOAE tests were done. The injections of 4 mg/mL dexamethasone were done 5 times in fixed protocols on days 0, 2, 4, 6, and 8. After each injection, the patients were kept supine for 60 minutes with the head turned 45 degrees to opposite ear. Paired t test was used to compare the beginning and final measurements.
Temporary pain and vertigo attacks which lasted at most for 15 minutes occurred in some patients only during injections. Neither infection nor persistent perforation occurred in any patients. After the management, there was no significant difference on patient's pure tone averages ( P = .067) and high-frequency averages ( P = .592). When the obtained TEOAE results before and after management were compared, the only significant increase was detected in the reproducibility values ( P = .042). There was no significant difference in other TEOAE parameters which are stimulus stability, stimulus intensity, and overall signal-to-noise ratio ( P > .05). There is no fixed criteria for rejecting a response solely on the reproducibility. However, a high value of the reproducibility (or increase in reproducibility) is always meaningful.
Intratympanic dexamethasone used for management in many indications, primarily in Meniere and tinnitus patients, was found to increase the reproducibility values of otoacoustic emission. Despite the fact that there was not a reasonable increase in the responses coming from the outer hair cells, the result was considered positive for the study as the responses did not decrease. It is found out that 4 mg/mL dexamethasone given intratympanically does not adversely affect the outer hair cell function as measured by otoacoustic emission. Within the limits of this study, dexamethasone appears to be safe when given intratympanically.
研究因耳鸣而进行的鼓室内注射地塞米松对瞬态诱发耳声发射(TEOAE)的影响,从而确定给予地塞米松是否会对内耳造成任何损害。
随机选取26例年龄在32至75岁之间的主观性耳鸣患者。这些入选患者是经过至少6个月的药物治疗(如银杏叶提取物EGb 761、倍他司汀和曲美他嗪)但病情未得到改善,且无全身性或耳鼻喉科疾病(高血压、糖尿病、甲状腺功能减退/亢进、高胆固醇血症、梅尼埃病和耳硬化症)的患者。在注射前后,进行包括高频耳鸣匹配和TEOAE测试在内的听力测定。按照固定方案,在第0、2、4、6和8天注射4mg/mL的地塞米松5次。每次注射后,患者保持仰卧位60分钟,头向对侧耳朵转动45度。采用配对t检验比较初始测量值和最终测量值。
仅部分患者在注射过程中出现了持续时间最长为15分钟的短暂疼痛和眩晕发作。所有患者均未发生感染或持续性鼓膜穿孔。治疗后,患者的纯音平均值(P = 0.067)和高频平均值(P = 0.592)无显著差异。比较治疗前后获得 的TEOAE结果时,仅在重复性值方面检测到显著增加(P = 0.042)。在刺激稳定性、刺激强度和总体信噪比等其他TEOAE参数方面无显著差异(P > 0.05)。目前尚无仅基于重复性来拒绝一个反应的固定标准。然而,高重复性值(或重复性增加)总是有意义的。
发现用于多种适应症(主要是梅尼埃病和耳鸣患者)治疗的鼓室内地塞米松可提高耳声发射的重复性值。尽管来自外毛细胞的反应没有合理增加,但由于反应没有降低,该结果在本研究中被认为是阳性的。结果表明,鼓室内给予4mg/mL地塞米松不会对通过耳声发射测量的外毛细胞功能产生不利影响。在本研究范围内,鼓室内给予地塞米松似乎是安全的。